Literature DB >> 28640379

Comparative and correlative assessments of cytokine, complement and antibody patterns in paediatric type 1 diabetes.

M Abdel-Latif1, A A Abdel-Moneim2, M H El-Hefnawy3, R G Khalil1.   

Abstract

One of the most widespread and effective environmental factors is the infection with enteroviruses (EVs) which accelerate β cell destruction in type 1 diabetes (T1D). This study represented a comparison between diabetic EV+ and EV- children as well as correlation analysis between autoantibodies, T1D markers, cytokines, complement activation products and anti-coxsackievirus (CV) immunoglobulin (Ig)G. EV RNA was detected in Egyptian children with T1D (26·2%) and healthy controls (0%). Detection of anti-CV IgG in T1D-EV+ resulted in 64% positivity. Within T1D-EV+ , previously diagnosed (PD) showed 74 versus 56% in newly diagnosed (ND) children. Comparisons between populations showed increased levels of haemoglobin A1c (HbA1c), C-reactive protein (CRP), nitric oxide (NO), glutamic acid decarboxylase and insulin and islet cell autoantibodies [glutamic acid decarboxylase autoantibodies (GADA), insulin autoantibodies (IAA) and islet cell cytoplasmic autoantibodies (ICA), respectively], interferon (IFN)-γ, tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL -10, IL -12, IL -17, C3d and sC5-9 in T1D-EV+ versus T1D-EV- . Conversely, both IL-20 and transforming growth factor (TGF-β) decreased in T1D-EV+ versus EV- , while IL-4, -6 and -13 did not show any changes. Correlation analysis showed dependency of accelerated autoimmunity and β cell destruction on increased IFN-γ, IL-12 and IL-17 versus decreased IL-4, -6 and -13. In conclusion, IFN-γ, IL-12 and IL-17 played an essential role in exacerbating EV+ -T1D, while C3d, sC5b -9, IL-10 and -20 displayed distinct patterns.
© 2017 British Society for Immunology.

Entities:  

Keywords:  complement; correlation; cytokines; enteroviruses; type 1 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28640379      PMCID: PMC5588772          DOI: 10.1111/cei.13001

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  49 in total

1.  Worldwide increase in incidence of Type I diabetes--the analysis of the data on published incidence trends.

Authors:  P Onkamo; S Väänänen; M Karvonen; J Tuomilehto
Journal:  Diabetologia       Date:  1999-12       Impact factor: 10.122

Review 2.  Enteroviruses and type 1 diabetes.

Authors:  Ruben Varela-Calvino; Mark Peakman
Journal:  Diabetes Metab Res Rev       Date:  2003 Nov-Dec       Impact factor: 4.876

3.  C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype.

Authors:  Sridevi Devaraj; Ishwarlal Jialal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-17       Impact factor: 8.311

Review 4.  Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes.

Authors:  Jasmin Lebastchi; Kevan C Herold
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

5.  Human pancreatic islet endothelial cells express coxsackievirus and adenovirus receptor and are activated by coxsackie B virus infection.

Authors:  Maria M Zanone; Enrica Favaro; Elena Ferioli; Guo C Huang; Nigel J Klein; Paolo Cavallo Perin; Mark Peakman; Pier G Conaldi; Giovanni Camussi
Journal:  FASEB J       Date:  2007-05-10       Impact factor: 5.191

6.  Reciprocal changes in complement activity and immune-complex levels during plasma infusion in a C2-deficient SLE patient.

Authors:  K Erlendsson; K Traustadóttir; J Freysdóttir; K Steinsson; I Jónsdóttir; H Valdimarsson
Journal:  Lupus       Date:  1993-06       Impact factor: 2.911

7.  Diabetogenic effects of the most prevalent enteroviruses in Finnish sewage.

Authors:  Paivi Klemola; Svetlana Kaijalainen; Petri Ylipaasto; Merja Roivainen
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 8.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

9.  Children with islet autoimmunity and enterovirus infection demonstrate a distinct cytokine profile.

Authors:  Wing-Chi G Yeung; Ammira Al-Shabeeb; Chi Nam Ignatius Pang; Marc R Wilkins; Jacki Catteau; Neville J Howard; William D Rawlinson; Maria E Craig
Journal:  Diabetes       Date:  2012-04-03       Impact factor: 9.461

10.  Increased complement activation in human type 1 diabetes pancreata.

Authors:  Patrick Rowe; Clive Wasserfall; Byron Croker; Martha Campbell-Thompson; Alberto Pugliese; Mark Atkinson; Desmond Schatz
Journal:  Diabetes Care       Date:  2013-09-16       Impact factor: 19.112

View more
  5 in total

Review 1.  Type 1 diabetes: where are we in 2017?

Authors:  Melanie Copenhaver; Robert P Hoffman
Journal:  Transl Pediatr       Date:  2017-10

Review 2.  Targeting Stem Cell-Derived Tissue-Associated Regulatory T Cells for Type 1 Diabetes Immunotherapy.

Authors:  Mohammad Haque; Jugal Kishore Das; Xiaofang Xiong; Jianxun Song
Journal:  Curr Diab Rep       Date:  2019-08-30       Impact factor: 4.810

3.  Elevated histone H3 acetylation is associated with genes involved in T lymphocyte activation and glutamate decarboxylase antibody production in patients with type 1 diabetes.

Authors:  Yanfei Wang; Can Hou; Jonathan Wisler; Kanhaiya Singh; Chao Wu; Zhiguo Xie; Qianjin Lu; Zhiguang Zhou
Journal:  J Diabetes Investig       Date:  2018-06-26       Impact factor: 4.232

4.  Association Between Enterovirus Infection and Type 1 Diabetes Risk: A Meta-Analysis of 38 Case-Control Studies.

Authors:  Kan Wang; Fei Ye; Yong Chen; Jianxin Xu; Yufang Zhao; Yeping Wang; Tian Lan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-07       Impact factor: 5.555

5.  Confirmation and Identification of Biomarkers Implicating Environmental Triggers in the Pathogenesis of Type 1 Diabetes.

Authors:  Robert Z Harms; Katie R Ostlund; Monina S Cabrera; Earline Edwards; Marisa Fisher; Nora Sarvetnick
Journal:  Front Immunol       Date:  2020-09-15       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.